Company Profile

Bioseek Inc: wholly owned subsiduary of DiscoverX
Profile last edited on: 3/22/19      CAGE: 4H0A4      UEI:

Business Identifier: Cell-based predictive assays
Year Founded
2000
First Award
2001
Latest Award
2004
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

310 Utah Avenue Suite 100
South San Francisco, CA 94080
   (650) 416-7600
   busdevelop@bioseekinc.com
   www.bioseekinc.com
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

In November 2010, Bioseek Inc was acquired by Asterand and then in November 2012, was sold to DiscoverX Corporation and now operate as a wholly owned subsiduary. Focused on applying human primary cell assays and predictive disease models to the discovery and development of human therapeutics and safer chemicals, BioSeek is a human systems biology drug discovery company harnessing the bioinformatics content and processing power of living human cell systems to decipher rapidly the functions of genes, proteins and drugs for more efficient and predictive pharmaceutical discovery. The firm's proprietary technologies are being applied for the identification, validation and commercialization of novel and improved human therapeutics. The BioSeek platform of human primary cell culture-based technologies utilize an innovative complex systems biology approach for earlier and more accurate selection of targets and compounds at all stages of preclinical and clinical development. With these, the company expects to dramatically reduce the time and cost of preclinical and clinical drug development, initially in the areas of inflammation, cardiovascular disease and oncology.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 2 NIH $857,795
Project Title: Flow cytometry for novel regulators of inflammation
2001 1 NIH $99,491
Project Title: Multiplex Assay For Genetic Regulations Of Inflammation

Key People / Management

  Rolf Ehrhardt -- President

  Ellen L Berg

  Peter Bluford -- Vice President of Business Development

Company News

There are no news available.